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Abstract: Sphingosine 1-phosphate (S1P) is an extensively studied signaling molecule that contributes
to cell proliferation, survival, migration and other functions through binding to specific S1P receptors.
The cycle of S1P1 internalization upon S1P binding and recycling to the cell surface when local S1P
concentrations are low drives T cell trafficking. S1P1 modulators, such as fingolimod, disrupt this
recycling by inducing persistent S1P1 internalization and receptor degradation, which results in
blocked egress of T cells from the secondary lymphoid tissues. The approval of these compounds for
the treatment of multiple sclerosis has placed the development of S1PR modulators in the focus of
pharmacological research, mostly for autoimmune indications. Here, we report on a novel anellated
bismorpholino derivative of oxy-fingolimod, named ST-2191, which exerts selective S1P1 agonist
and functional antagonist potency. ST-2191 is also effective in reducing the lymphocyte number in
mice, and this effect is not dependent on phosphorylation by sphingosine kinase 2 for activity. These
data show that ST-2191 is a novel S1P1 modulator, but further experiments are needed to analyze the
therapeutic impact of ST-2191 in animal models of autoimmune diseases.
Keywords: sphingosine 1-phosphate; S1P1 receptor; functional antagonism; lymphopenia; ST-2191;
anellated bismorpholino
1. Introduction
Based on the LIPID MAPS classification system, sphingolipids represent one out
of the eight categories of lipids [1,2]. They are now increasingly recognized as not only
structural components of biological membranes but as bioactive molecules regulating
multiple physiological and pathophysiological processes. Sphingosine 1-phosphate (S1P)
is an extensively studied example of a signaling sphingolipid that contributes to cell
proliferation and survival, migration, differentiation, cellular remodeling and extracellular
matrix production [3]. The first step in these cellular responses is the binding of S1P
to specific high-affinity cell surface receptors (S1PRs), of which five subtypes have been
described, named S1P1, S1P2, S1P3, S1P4 and S1P5 [4,5]. These receptors belong to the
superfamily of G-protein coupled receptors (GPCR). Every cell type and organ so far
studied expresses one or several S1PR, which have distinct or overlapping downstream
effector molecules; thus, each cell type is influenced in a unique way [6]. Moreover, the
concentration of S1P in various body compartments, such as blood or secondary lymphoid
organs, varies drastically, which may even trigger opposite reactions by the same cells.
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As observed for several other GPCRs, which internalize upon ligand binding and
receptor activation [7], S1P1 also internalizes upon S1P binding. This is a complex and
reversible process, which depends on the concentration gradient of S1P, and is fundamental
for T cell trafficking. In environments with high levels of S1P, such as the blood, S1P1
is internalized and is not detectable at the surfaces of T cells, which allows homing in
secondary lymphoid tissues [8]. In secondary lymphoid tissues, where S1P levels are
extremely low, S1P1 reappears on the surface and enables sensing of the high gradient
of S1P in the lymph [8]. This directs the egress of T cells, i.e., the exit from secondary
lymphoid tissues.
FTY720 (fingolimod) in its phosphorylated form resembles the structure of S1P and
was found to activate all S1P receptor subtypes except S1P2 [9]. In 2010, fingolimod
became the first S1PR modulator that received marketing authorization for the treatment
of relapsing–remitting multiple sclerosis [10]. The approval of fingolimod has placed the
development of S1PR modulators in the focus of pharmacological research, mostly for
autoimmune indications [11]. Recently, the more selective S1PR modulators siponimod,
ponesimod and ozanimod were also approved by the European Medicines Agency (EMA)
for the treatment of multiple sclerosis, and ozanimod by the FDA for the treatment of
ulcerative colitis. The area of S1PR modulators is expanding and molecules with structures
related or unrelated to S1P, with unselective or selective affinities, with an agonistic or
antagonistic mode of action, are being introduced [5]. Targeting S1P1 is of particular
interest for the novel modulators, because of the key role of S1P1 in T cell trafficking. As
opposed to the endogenous ligand S1P, synthetic S1P1 modulators, such as fingolimod,
siponimod, ozanimod and ponesimod, induce permanent internalization upon binding to
and activation of S1P1 [12–15]. Such internalization, which is not followed by recycling to
the cell surface, depletes the number of T cells in the blood as they become unresponsive to
the S1P gradient [16]. T cells remain in the secondary lymphoid tissues and the result is an
immune modulation that is necessary for autoimmune and inflammatory diseases, where
T cells play a major pathological role [17].
Previously, we developed two morpholino analogues of fingolimod (ST-1893 and ST-
1894), which showed a selective S1P1 activation profile and sustained S1P1 internalization
consistent with a functional antagonism. Both compounds induced profound lymphopenia
in mice and were efficacious in the experimental autoimmune encephalomyelitis model
of multiple sclerosis [18]. Here, we report on two novel compounds, ST-2191, which is an
anellated bismorpholino derivative of oxy-fingolimod, and ST-2192, which is a fusion of
two oxy-analogues of fingolimod by a N,N’-dimethylene bridge. ST-2191 potently activated
S1P1 in the low micromolar range, but it had no effect on any of the other S1PRs. Compared
to ST-2191, ST-2192 had only a minor effect on S1P1. We further characterized ST-2191 as a
functional antagonist of S1P1 with in vivo efficacy in reducing the number of lymphocytes
in mice. Moreover, and in contrast to FTY720, this substance still induced lymphopenia
in Sphk2-deficient mice, thus highlighting its “non-pro-drug” property. Further studies
are warranted to confirm the potential of ST-2191 as a selective S1P1 modulator in animal
models of autoimmune diseases.
2. Results
ST-2191 (9a-(4-(heptyloxy)phenethyl)hexahydro-1H,3H-[1,4]oxazino [3,4-c][1,4]
oxazine) is structurally related to the previously reported S1P1 selective modulator ST-1894
(Figure 1) [18]. Both can be synthesized using the oxy-analogue of fingolimod [19] as a
precursor (Supplementary File). The same reaction yielded another product, ST-2192,
which contains two oxy-analogues of fingolimod fused by a N,N’-dimethylene bridge.
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Figure 1. Scheme of the chemical synthesis route for ST-2191 starting from the oxy-analogue of fingolimod (O-FTY). The 
main product of this reaction is ST-2192 (30%), while ST-1894 (15%) (see also [18]) and ST-2191 (5%) were generated as 
side products. Synthesis details can be found in the Supplementary File. (a) 1,2-dibromoethane, acetone; (b) crystallization 
with acetone, DCM/ammonia; (c) extraction with DCM; (d) flash chromatography with DCM/methanol. 
A common feature of all S1P receptor modulators so far approved for the treatment 
of multiple sclerosis or ulcerative colitis is the targeting of S1P1. Interaction with S1P1 is of 
primary importance in the development of novel S1PR modulators due to the lymphope-
nic effects that this interaction may produce [5]. Thus, in a first step, we employed molec-
ular modelling and energy minimization experiments using a homologue model of an 
activated S1P1 receptor (Figure 2, Supplementary Figure S1). The nitrogen atom of the 
anellated bismorpholino moiety (an oxazino-oxazine) interacted with Glu-121 and Glu294 
(H-acceptors), while the oxygen interacted with Asn-101 (H-donor). The phenyl moiety 
interacted with the hydrophobic residue Leu-297 (π-H). Other amino acids that interact 
with atoms of ST-2191 include: Val-298, Phe-125, Leu-276, Leu-195, Met-124, Trp-269, Cys-
206, Ser-105 and others. This, together with the data from the energy minimization of the 
whole system (protein S1P1 and ST-2191) and the energy calculations of the ligand in the 
active site performed on it, with the corresponding binding affinity score and binding 
enthalpy (Supplementary Table S1), indicated a good docking of ST-2191 and predicted 
an interaction with S1P1, which needed to be confirmed in a cellular system.  
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Figure 2. Two-dimensional molecular model of interactions between ST-2191 and amino acid residues of the binding 
pocket of the S1P1 receptor. Molecular modelling experiments were performed as explained in the Materials and Methods 
section. Green colored circles represent hydrophobic amino acids, while pink circles represent polar amino acids. Red 
contour is drawn around the acidic and blue around basic amino acids. The blue clouds in the structure of ST-2191 indicate 
the surface exposed to the solvent, while the blue halo around some amino acids indicates an interaction with the ligand, 
where a larger halo means a stronger interaction. Hydrogen bonds are represented by green arrows. 
To characterize the S1P receptor activation profile of ST-2191, we used CHO-K1 cells, 
which stably overexpress the different S1P receptor subtypes, i.e., S1P1, S1P2, S1P3, S1P4 
and S1P5. These cells were stimulated with increasing concentrations of the compounds, 
or with S1P as a positive control. Activation of the receptors was detected by increased 
phosphorylation of p42/p44-MAPK, which is a well reported early read-out of S1P recep-
tor activation [20,21]. In all S1PR-overexpressing cells, S1P dose-dependently activated 
the receptors, with effects already seen in the lower nM range, thus confirming previous 
studies of S1PR characterization [22,23]. ST-2191, up to 3 μM, only activated the S1P1, but 
failed to activate the other receptor subtypes, suggesting that the compound is a selective 
S1P1 agonist (Figure 3A). ST-2192 only slightly activated S1P1 at the highest concentration 
of 3 μM (28% of the ST-2191 effect at 3 μM) and was thus discontinued from further stud-
ies (Figure 3B). The half-maximal effective concentration (EC50) of ST-2191 for the activa-
tion of p42/p44-MAPK in CHO-S1P1 was 1.99 μM (Figure 3C). 
Figure 2. Two-dimensional molecular model of interactions between ST-2191 and amino acid residues of the binding pocket
of the S1P1 receptor. Molecular modelling experiments were performed as explained in the Materials and Methods section.
Green colored circles represent hydrophobic amino acids, while pink circles represent polar amino acids. Red contour is
drawn around the acidic and blue around basic amino acids. The blue clouds in the structure of ST-2191 indicate the surface
exposed to the solvent, while the blue halo around some amino acids indicates an interaction with the ligand, where a larger
halo means a stronger interaction. Hydrogen bonds are represented by green arrows.
To characterize the S1P receptor activation profile of ST-2191, we used CHO-K1 cells,
which stably overexpress the different S1P receptor subtypes, i.e., S1P1, S1P2, S1P3, S1P4
and S1P5. These cells were stimulated with increasing concentrations of the compounds,
or with S1P as a positive control. Activation of the receptors was detected by increased
phosphorylation of p42/p44-MAPK, which is a well reported early read-out of S1P receptor
activation [20,21]. In all S1PR-overexpressing cells, S1P dose-dependently activated the
receptors, with effects already seen in the lower nM range, thus confirming previous studies
of S1PR characterization [22,23]. ST-2191, up to 3 µM, only activated the S1P1, but failed
to activate the other receptor subtypes, suggesting that the compound is a selective S1P1
agonist (Figure 3A). ST-2192 only slightly activated S1P1 at the highest concentration of
3 µM (28% of the ST-2191 effect at 3 µM) and was thus discontinued from further studies
(Figure 3B). The half-maximal effective concentration (EC50) of ST-2191 for the activation of
p42/p44-MAPK in CHO-S1P1 was 1.99 µM (Figure 3C).
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Figure 3. S1P receptor activation profile of ST-2191. CHO cells overexpressing the S1P1, S1P2, S1P3, S1P4 or S1P5 were 
stimulated for 10 min with vehicle (DMSO, ctrl), S1P (A,B), ST-2191 (A,B) or ST-2192 (B) in serum-free medium and were 
further processed for Western blot detection of phospho-p42/p44-MAPK and total p42/p44, as explained in the Materials 
and Methods section. Blots show one representative out of three independent experiments. (C) Bands of phospho-p42/p44-
MAPK were quantified by using ImageJ software. Results are presented as means ± S.E.M. (n = 3). * p < 0.05, ** p < 0.01, 
**** p < 0.0001 compared to DMSO-treated control. A non-linear regression analysis was used to calculate the half-maximal 
effective concentration (EC50) of ST-2191 for the S1P1 (R2 = 0.96) as 1.99 μM. 
It was important to analyse whether ST-2191 behaves similarly to fingolimod in in-
ducing sustained internalization of S1P1 after the initial step of agonistic activation. Incu-
bation of CHO-S1P1 cells for 3 h with either S1P or ST-2191, prior to stimulation with S1P 
for 10 min, downregulated the phosphorylation of p42/p44-MAPK (Figure 4A) consistent 
with internalized receptor. When a wash-out step was included after 3 h, and cells were 
allowed to recover for further 21 h, cells became again responsive to short-term S1P stim-
ulation only in the case of S1P pretreatment/recovery, but not in the case of ST-2191 pre-
treatment/recovery setup (Figure 4B). This suggests that prolonged ST-2191 treatment, 
even at a half-maximal effective concentration, desensitizes S1P-induced p42/p44-MAPK 
activation, possibly through the downregulation of the S1P1 receptor’s surface expression.  
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2191 reduced the cell surface-expressed S1P1 after either 3 h treatment (Figure 5A) or 3 h
treatment plus subsequent wash-out/recovery for 21 h (Figure 5B). Moreover, 3 h S1P
stimulation decreased cell surface S1P1; however, after the wash-out/recovery period, S1P1
reappeared on the cell surface. This confirms the previously reported receptor dynamics
in the presence and absence of S1P and emphasizes the different internalization patterns
triggered by ST-2191.
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Based on these data, ST-2191 possesses the structural characteristics necessary for
rapid S1P1 activation and a subsequent sustained S1P1 internalization in vitro. To translate
these findings in vivo, we treated mice with a single dose injection of 1 mg/kg ST-2191 and
measured the number of lymphocytes in blood after 24 h. The number of lymphocytes was
significantly decreased in the ST-2191-treated group compared to the vehicle-treated group
(Figure 6), which can be explained by the sustained S1P1 internalization property of ST-2191.
We suggest that ST-2191 decreases S1P1 on the surfaces of T cells and thereby prevents
their egress into the blood, leading to lymphopenia. Notably, such a lymphopenic effect
Molecules 2021, 26, 5134 7 of 12
is critical for the immunomodulatory action of fingolimod, siponimod and ponesimod in
multiple sclerosis, and of ozanimod in ulcerative colitis.
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Figure 6. ST-2 91-induce decrease in lymphocyte numbers in mice. Wildtype mice (wt) or mice
deficient in Sphk2 (Sphk2 ko) were injected in the peritoneum with a single dose of 1 mg/kg ST-2191
(in DMSO/PBS) or vehicle (DMSO in PBS), and after 24 h, blood was collected and lymphocyte
number was measured as explained in the Materials and Methods section. Results are presented
as means ± S.E.M. (n = 5 in each group) and significance was calculated by Mann–Whitney U test
(** p < 0.01 compared to vehicle-treated wt mice; ## p < 0.01 compared to vehicle-treated Sphk2
ko mice).
Several S1PR modulators, such as fingolimod, amiselimod and mocravimod, are
prodrugs that exert their immunomodulatory role only after Sphk2-catalyzed phospho-
rylation [12,24,25]. Therefore, we tested the effect of ST-2191 on lymphocyte number in
mice with global Sphk2 knockout and found that the lymphopenic effect was still present,
although reduced, in the absence of Sphk2 (Figure 6). This suggests that ST-2191 does not
depend on Sphk2 for its immuno odulatory activity, but it does not rule out whether other
active metabolites can be formed in vivo. Notably, the dual S1P1+5 odulator ozanimod,
which is currently in clinical trials for multiple sclerosis, inflammatory bowel disease and
COVID-19, is metabolized to two active structures, which produce most of the clinical
effects of the drug [26].
3. Discussion
In this s udy, using oxy-fi golimod s a precursor, we synthesized ST-2191, a novel
compound with an interesting new anellated bismorpholino moiety. This compound
showed a selective S1P1 agonistic and functional antagonistic activation profile and reduced
the lymphocyte number in mice, demonstrating an immunomodulatory effect that is
desired for the treatment of various autoimmune and inflammatory diseases [5].
ST-2191 can be synthesized in an analogous route to that of ST-1894, a previously
reported S1P1 receptor modulator with a morpholino moiety (Figure 1) [18]. Furthermore,
ST-2191, which is an anellated bismorpholino derivative by the formal condensation
of two morpholine rings, i.e., perhydro[1,4]oxazino[3,4-c][1,4]oxazine derivative of oxy-
fingolimod, strongly resembles the oxazolo-oxazolo derivative ST-1071 [20], but contains a
larger polar head group. The trigger for agonism on the S1P1 receptor is associated with
Molecules 2021, 26, 5134 8 of 12
an increase in binding pocket volume and ligands with larger volume can have a more
hampered dissociation, which could lead to higher activity [18,27]. However, it seems
that there is a limitation to the volume of the ligand that can be accommodated in the
binding pocket. Notably, we have seen that ST-2192, which is a fusion of two symmetrical
molecules of oxy-fingolimod by the N-N’-dimethylene bridge, cannot properly fit into the
molecular model of S1P1 and, at 3 µM, can only slightly activate S1P1 (Figure 3B). On the
contrary, molecular modelling experiments, using a homologue model of an activated S1P1,
predicted good binding for ST-2191 (Figure 2) and the binding affinity was estimated in a
high nM or low µM concentration range. This was confirmed by the activation of S1P1 in
CHO-S1P1 cells measured by phosphorylation of p42/p44-MAPK (Figure 3C). The EC50
value of ST-2191 for S1P1 activation was determined as 1.99 µM (Figure 3C).
Contrasting the findings for fingolimod, ST-2191 selectively activates S1P1 but no other
S1P receptors (Figure 3A). All recently approved S1PR modulators have a more restricted ac-
tivation profile, where targeting S1P1 is still in the focus due to the lymphodepleting effects.
Conversely, some of the side effects or beneficial effects of fingolimod may be attributed
to the unselective engagement with other S1P receptors. In this regard, cerebrovascular
constriction during fingolimod treatment is believed to be a S1P3-mediated event [28],
while interaction with S1P5 has been associated with protection against demyelination
and the promotion of remyelination in both in vitro and in vivo animal studies [29]. The
S1P4-mediated effects of fingolimod are, so far, vague [5], although, recently, anti-allergic
and anti-inflammatory effects were demonstrated when S1P4 was antagonized [30].
ST-2191 conserved its lymphodepleting effect in the absence of Sphk2, unlike fin-
golimod, which is a pro-drug and becomes active upon phosphorylation by Sphk2 [31]. It
seems obvious that, under situations where Sphk2 is inhibited in patients—for example,
when treated with a Sphk2 inhibitor—the use of fingolimod-like pro-drugs is contraindi-
cated. However, such inhibitors are not yet approved but have reached clinical study phases
for various indications including cancer. Most advanced is the Sphk2 inhibitor ABC294640
(Opaganib, Yeliva®), which has received an orphan drug status for the treatment of cholan-
giocarcinoma and is presently being tested in a phase 2/3 trial for SARS-CoV-2-induced
pneumonia (NCT04467840). Hypothetically, Sphk2 polymorphisms may also hamper the
use of S1PR modulator pro-drugs. Thus far, polymorphisms of Sphk2 have only been
described for its promoter region, which affect the expression of the enzyme [32]. Overall,
current S1PR modulators have disparate metabolisms, and while some become active with-
out any modifications, others become active after phosphorylation by Sphk2 (fingolimod,
mocravimod, amiselimod [24,25]), or a series of reactions by various enzymes to produce
active metabolites such as ozanimod [26]. This highlights the need to dissect the in vivo
metabolites that are produced following ST-2191 administration.
Altogether, our data show the synthesis and first characterization of ST-2191 as a
selective S1P1 modulator with in vivo activity on lymphocyte counts. However, it remains
to be shown whether ST-2191 has the potential to become a therapeutic drug, and further
experiments are needed to analyze the effectiveness of this substance in animal models of
autoimmune diseases.
4. Materials and Methods
4.1. Chemicals and Chemical Synthesis of ST-2191
All chemicals are listed in the Supplementary File. The chemical synthesis steps of
ST-2191 are summarized in Figure 1 and described in detail in the Supplementary File.
4.2. Molecular Modelling
Molecular modelling, energy minimization experiments and dynamics simulations
were performed as previously explained [33].
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4.3. Cell Culture
Chinese hamster ovary (CHO)-K1 cells overexpressing human S1P1, S1P2, S1P3, S1P4
or S1P5 receptor were a kind gift from Dr. Danilo Guerini (Novartis Institutes for Biomedical
Research, Basel, Switzerland). CHO-S1P1, CHO-S1P4 and CHO-S1P5 were cultivated in
MEM alpha with nucleosides and stable glutamine supplemented with 10% FBS, 10 mM
HEPES, 50 µg/mL gentamycin and 0.5 mg/mL G418 for selection. CHO-S1P2 and CHO-
S1P3 were grown in RPMI-1640 with the same supplements as above. Cells were detached
from the flasks by 0.25% Trypsin–EDTA and seeded on 60 mm dishes at a concentration of
500,000 cells in 3 mL medium. After achieving confluency, they were placed overnight in a
serum-free medium consisting of DMEM, 0.1 mg/mL bovine serum albumin (BSA) and
10 mM HEPES (later abbreviated as serum-free medium).
4.4. Cell Stimulation and Western Blot Analysis
After 20 h starvation in serum-free medium, CHO-K1 cells in 60 mm dishes were
stimulated with vehicle (DMSO), S1P, ST-2191 or ST-2192 in serum-free medium for 10 min.
Thereafter, cells were washed with ice-cold PBS, scraped into lysis buffer and homogenized
by sonication, as previously explained [34]. Lysates were centrifuged at 13,000 rpm for
10 min and supernatants were dissolved in 4× Laemmli buffer consisting of 4 mM EDTA,
40 mM Tris pH 7.4, 53% glycerol, 13% SDS, 181 µM DTT and 0.448 mM bromophenol
blue to a 1x final concentration. Volumes were adapted in order to equalize the amount
of protein after previous quantification according to Bradford. Samples were boiled at
95 ◦C for 10 min prior to loading in 10% (bis-)acrylamide gels and proteins were separated
by SDS-PAGE and transferred to nitrocellulose membrane by semi-dry blotting for 7 min
(Trans-Blot Turbo™ by Bio-Rad Laboratories AG, Cressier, Switzerland). Membranes were
blocked with 3% (w/v) low-fat milk powder in PBS for 1 h at room temperature and
were incubated overnight at 4oC with primary antibody in a blocking buffer consisting of
50 mM Tris-HCl pH 7.4, 200 mM NaCl, 10% (v/v) horse serum, 3% (w/v) BSA fraction V
and 0.1% (v/v) Tween20. Phospho-p42/p44-MAPK was from Cell Signaling (No. 4377,
dilution 1:1000) and polyclonal antibodies against p42-MAPK and p44-MAPK were in-
house generated [35] and used in a dilution of 1:3000. After washing 3 times for 7 min with
0.1% Tween in PBS, IRDye® 800 CW secondary antibody was added, diluted in a blocking
buffer at 1:10,000 and was allowed to incubate for 2 h at room temperature. Membranes
were washed as before and scanned with an Odyssey machine by LI-COR Biosciences (Bad
Homburg, Germany) and the signal intensity was evaluated by ImageJ (National Institutes
of Health, Bethesda, MD, USA).
4.5. S1P1 Internalization ELISA
For the S1P1 internalization ELISA, CHO-S1P1 cells that stably overexpressed an
N-terminally Myc-tagged human S1P1 construct were used. The ELISA was performed
exactly as described before, but with a change in the concentration of S1P and ST-2191 [18],
using Myc-tag primary (Cell Signaling, No. 2276, 1:1000) and anti-mouse HRP-linked
secondary antibody (Cell Signaling, No. 7076, 1:5000).
4.6. Lymphocyte Count
All animal experiments were approved by the committee of animal experimentation
of the Veterinary Department of the Canton of Bern, under approval number BE-50/17.
C57BL/6J mice were provided by Janvier Labs (France). Sphk2tm1geno were generated by
GenOway S.A. (Lyon, France). C57BL/6J wildtype or Sphk2 knockout mice were injected
in the peritoneum with a single dose of 1 mg/kg ST-2191 or DMSO in PBS, and after
24 h, blood was collected from the heart under terminal isoflurane-induced anesthesia in
EDTA-K3 coated microvettes (Sarstedt; Sevelen, Switzerland). The number of lymphocytes
was measured with a Scil Vet ABC™ Hemocytometer and was expressed per one liter of
blood (Scil Animal Care Company GmbH; Viernheim, Germany).
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4.7. Statistical Analysis
Statistical analysis and graph creation were carried out in GraphPad Prism 6 (La Jolla,
CA, USA). Statistical significance was calculated with ordinary one-way ANOVA without
matching or unpaired t-test, and data are presented as a mean ± S.D. for n number of
independent experiments, unless otherwise stated.
Supplementary Materials: The following are available online, Figure S1: Ligandscout plot showing
interaction of ST-2191 with S1P1; Table S1: Energy calculation with Ligandscout [18,36,37].
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